PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
PALVELLA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$122.96+2.66 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$49.81 (+68.09%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.77B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.14
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$61.70M
- EPS, diluted
- -$4.82
- Book value per share
- $15.11
- Diluted shares
- 14M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$57.74M
Net income
-$61.70M
EPS, diluted
-$4.82
Free cash flow
–
Reported periodTrailing twelve months